Medexus Financial Statements From 2010 to 2025
| MEDXF Stock | USD 2.13 0.11 5.45% |
Check Medexus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Medexus Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Medexus financial statements analysis is a perfect complement when working with Medexus Pharmaceuticals Valuation or Volatility modules.
Medexus |
Medexus Pharmaceuticals OTC Stock Return On Asset Analysis
Medexus Pharmaceuticals' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Medexus Pharmaceuticals Return On Asset | 0.0218 |
Most of Medexus Pharmaceuticals' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medexus Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Medexus Pharmaceuticals has a Return On Asset of 0.0218. This is 100.25% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The return on asset for all United States stocks is 115.57% lower than that of the firm.
Medexus Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Medexus Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Medexus Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Medexus Pharmaceuticals competition to find correlations between indicators driving Medexus Pharmaceuticals's intrinsic value. More Info.Medexus Pharmaceuticals is rated below average in return on equity category among its peers. It is regarded third in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Medexus Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Medexus Pharmaceuticals Financial Statements
Medexus Pharmaceuticals stakeholders use historical fundamental indicators, such as Medexus Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Medexus Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Medexus Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Medexus Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Medexus Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 100 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Medexus OTC Stock
Medexus Pharmaceuticals financial ratios help investors to determine whether Medexus OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medexus with respect to the benefits of owning Medexus Pharmaceuticals security.